vs
Side-by-side financial comparison of MODIV INDUSTRIAL, INC. (MDV) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
MODIV INDUSTRIAL, INC. is the larger business by last-quarter revenue ($11.1M vs $9.3M, roughly 1.2× STRATA Skin Sciences, Inc.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs 0.6%, a 10.3% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -5.6%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -3.8%).
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
MDV vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $9.3M |
| Net Profit | $1.2M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 45.8% | 5.3% |
| Net Margin | 11.0% | 0.6% |
| Revenue YoY | -5.6% | -3.0% |
| Net Profit YoY | -22.0% | 101.3% |
| EPS (diluted) | $0.02 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $9.3M | ||
| Q3 25 | $11.7M | $6.9M | ||
| Q2 25 | $11.8M | $7.7M | ||
| Q1 25 | $11.8M | $6.8M | ||
| Q4 24 | $11.7M | $9.6M | ||
| Q3 24 | $11.7M | $8.8M | ||
| Q2 24 | $11.4M | $8.4M | ||
| Q1 24 | $12.0M | $6.8M |
| Q4 25 | $1.2M | $58.0K | ||
| Q3 25 | $1.0M | $-1.6M | ||
| Q2 25 | $-2.0M | $-2.6M | ||
| Q1 25 | $829.0K | $-2.1M | ||
| Q4 24 | $1.6M | $-4.6M | ||
| Q3 24 | $-587.0K | $-2.1M | ||
| Q2 24 | $1.3M | $-91.0K | ||
| Q1 24 | $3.7M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 45.8% | 5.3% | ||
| Q3 25 | 41.4% | -16.9% | ||
| Q2 25 | 9.8% | -30.1% | ||
| Q1 25 | 40.2% | -25.0% | ||
| Q4 24 | 45.4% | -44.7% | ||
| Q3 24 | 42.0% | -18.2% | ||
| Q2 24 | 44.6% | -5.7% | ||
| Q1 24 | 55.6% | -42.7% |
| Q4 25 | 11.0% | 0.6% | ||
| Q3 25 | 9.0% | -23.4% | ||
| Q2 25 | -17.1% | -33.6% | ||
| Q1 25 | 7.0% | -31.2% | ||
| Q4 24 | 13.3% | -47.6% | ||
| Q3 24 | -5.0% | -23.6% | ||
| Q2 24 | 11.6% | -1.1% | ||
| Q1 24 | 31.1% | -49.8% |
| Q4 25 | $0.02 | $0.14 | ||
| Q3 25 | $0.00 | $-0.36 | ||
| Q2 25 | $-0.32 | $-0.62 | ||
| Q1 25 | $-0.01 | $-0.51 | ||
| Q4 24 | $0.07 | $-2.01 | ||
| Q3 24 | $-0.18 | $-0.51 | ||
| Q2 24 | $0.03 | $-0.03 | ||
| Q1 24 | $0.33 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $7.9M |
| Total DebtLower is stronger | $261.5M | $15.3M |
| Stockholders' EquityBook value | $162.7M | $2.9M |
| Total Assets | $476.5M | $30.5M |
| Debt / EquityLower = less leverage | 1.61× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $7.9M | ||
| Q3 25 | $8.3M | $7.1M | ||
| Q2 25 | $5.8M | $6.0M | ||
| Q1 25 | $6.2M | $6.5M | ||
| Q4 24 | $11.5M | $7.3M | ||
| Q3 24 | $6.8M | $7.1M | ||
| Q2 24 | $18.9M | $5.5M | ||
| Q1 24 | $18.4M | $5.2M |
| Q4 25 | $261.5M | $15.3M | ||
| Q3 25 | $279.7M | $15.3M | ||
| Q2 25 | $279.7M | $15.0M | ||
| Q1 25 | $279.7M | $15.0M | ||
| Q4 24 | $279.8M | $15.0M | ||
| Q3 24 | $279.7M | $15.0M | ||
| Q2 24 | $279.7M | $15.0M | ||
| Q1 24 | $279.6M | $15.0M |
| Q4 25 | $162.7M | $2.9M | ||
| Q3 25 | $164.8M | $1.3M | ||
| Q2 25 | $165.6M | $532.0K | ||
| Q1 25 | $171.1M | $3.0M | ||
| Q4 24 | $190.1M | $5.0M | ||
| Q3 24 | $186.3M | $9.4M | ||
| Q2 24 | $187.0M | $9.5M | ||
| Q1 24 | $188.0M | $9.4M |
| Q4 25 | $476.5M | $30.5M | ||
| Q3 25 | $499.6M | $30.7M | ||
| Q2 25 | $498.9M | $29.5M | ||
| Q1 25 | $506.8M | $33.0M | ||
| Q4 24 | $507.8M | $34.9M | ||
| Q3 24 | $507.4M | $39.4M | ||
| Q2 24 | $519.5M | $38.8M | ||
| Q1 24 | $522.5M | $39.2M |
| Q4 25 | 1.61× | 5.28× | ||
| Q3 25 | 1.70× | 11.65× | ||
| Q2 25 | 1.69× | 28.20× | ||
| Q1 25 | 1.63× | 5.04× | ||
| Q4 24 | 1.47× | 3.02× | ||
| Q3 24 | 1.50× | 1.60× | ||
| Q2 24 | 1.50× | 1.58× | ||
| Q1 24 | 1.49× | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | 12.34× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.0M | $-239.0K | ||
| Q3 25 | $4.1M | $-64.0K | ||
| Q2 25 | $3.9M | $-1.9M | ||
| Q1 25 | $3.0M | $-550.0K | ||
| Q4 24 | $18.2M | $703.0K | ||
| Q3 24 | $5.1M | $-302.0K | ||
| Q2 24 | $4.7M | $591.0K | ||
| Q1 24 | $3.0M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | 12.34× | -4.12× | ||
| Q3 25 | 3.95× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.68× | — | ||
| Q4 24 | 11.72× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.55× | — | ||
| Q1 24 | 0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MDV
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
